Clinical Trial Update: An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update reporting completion of an eight-week study evaluating two doses of saredutant in adults with generalized anxiety disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• Saredutant (saredutant)

Snippet

Sponsor: Sanofi | Conditions: Generalized Anxiety | Phase 3 | Status: COMPLETED